D-dimer

Global Hemostasis Diagnostics Market to Reach $2.7 Billion by 2027 with a 4.8% CAGR - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 24, 2022

In the changed post COVID-19 business landscape, the global market for Hemostasis Diagnostics estimated at US$2 Billion in the year 2020, is projected to reach a revised size of US$2.7 Billion by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027.

Key Points: 
  • In the changed post COVID-19 business landscape, the global market for Hemostasis Diagnostics estimated at US$2 Billion in the year 2020, is projected to reach a revised size of US$2.7 Billion by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027.
  • Prothrombin Test Time (PT), one of the segments analyzed in the report, is projected to record a 4.5% CAGR and reach US$1.1 Billion by the end of the analysis period.
  • China, the world's second largest economy, is forecast to reach a projected market size of US$561.5 Million by the year 2027 trailing a CAGR of 8.5% over the analysis period 2020 to 2027.
  • In the global Fibrinogen segment, USA, Canada, Japan, China and Europe will drive the 4.9% CAGR estimated for this segment.

Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients

Retrieved on: 
Thursday, June 30, 2022

New York, NY, and Tel Aviv, ISRAEL, June 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced biomarker data from its majority-owned joint venture 3CL Pharma Ltd.’s Phase 2 clinical trial of Tollovir™ in hospitalized COVID-19 patients. The data showed a positive correlation between the clinical data announced for Tollovir on January 27, 2022 and biomarkers associated with acute phase immune response (IL-6), inflammation (C reactive protein), blood clotting (D-dimer) and immune response to COVID-19 (cPass neutralizing antibodies). Additionally, renal and hepatic biomarker data showed no signals of treatment-associated risk with Tollovir therapy.

Key Points: 
  • Additionally, renal and hepatic biomarker data showed no signals of treatment-associated risk with Tollovir therapy.
  • Recent peer reviewed literature shows the predictability of key biomarker data such as IL-6, CRP, and D-Dimer in the hospitalized setting.
  • We believe the correlative biomarker data, in addition to the positive clinical results previously reported in hospitalized patients primarily from the Delta variant wave,should elevate Tollovirs profile in the eyes of regulators, said Gerald Commissiong, President & CEO of Todos Medical and Interim-CEO of 3CL Pharma.
  • Tollovir has successfully completed a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19.

LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test

Retrieved on: 
Thursday, June 2, 2022

The LumiraDx NT-proBNPand the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test.

Key Points: 
  • The LumiraDx NT-proBNPand the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test.
  • D-Dimer testing is widely accepted as the first step in the management of patients suspected of VTE.
  • LumiraDx has, on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform.
  • In addition, LumiraDx has a comprehensive portfolio of fast, accurate, and cost-efficient COVID-19 testing solutions from the lab to point of need.

LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test

Retrieved on: 
Thursday, June 2, 2022

The LumiraDx NT-proBNPand the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test.

Key Points: 
  • The LumiraDx NT-proBNPand the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test.
  • D-Dimer testing is widely accepted as the first step in the management of patients suspected of VTE.
  • LumiraDx has, on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform.
  • In addition, LumiraDx has a comprehensive portfolio of fast, accurate, and cost-efficient COVID-19 testing solutions from the lab to point of need.

Global D-dimer Testing Market Industry Analysis Report 2021-2028 - A US$1.83 Billion Market by 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 18, 2021

The "D-dimer Testing Market Share, Size, Trends, Industry Analysis Report, By Product; By Testing Method; By Application; By End-Use; By Regions; Segment Forecast, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "D-dimer Testing Market Share, Size, Trends, Industry Analysis Report, By Product; By Testing Method; By Application; By End-Use; By Regions; Segment Forecast, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global D-dimer testing market is expected to reach US$1.83 billion by 2028.
  • The global market for D-dimer testing is fragmented based on the product, method, application, end-use, and region.
  • The reagents & consumables market segment accounted for the largest revenue share of the global D-dimer testing industry in 2020 owing to the availability of ready made aptamers.

Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020

Retrieved on: 
Sunday, December 13, 2020

The primary biomarker endpoint of the study was within-group changes in high-sensitivity C-reactive protein (hsCRP), a measure of inflammation.

Key Points: 
  • The primary biomarker endpoint of the study was within-group changes in high-sensitivity C-reactive protein (hsCRP), a measure of inflammation.
  • VASCEPA administration resulted in a 25% reduction in hsCRP (p=0.011) as well as a reduction in D-dimer (p=0.048).
  • VASCEPA CardioLink-9 Study is an investigator-initiated study supported by Amarin and by HLS Therapeutics, Inc.
  • This presentation of CardioLink-9 study results was one of multiple data presentations at the NLA Scientific Sessions supported by Amarin.

Global D-dimer Testing Industry

Retrieved on: 
Wednesday, November 18, 2020

US D-dimer Testing Market Share (in %) by Company: 2019 & 2025

Key Points: 
  • US D-dimer Testing Market Share (in %) by Company: 2019 & 2025
    Projections in US$ Thousand by Testing Method: 2020 to 2027
    in US$ Thousand by Application: 2020 to 2027
    Forecasts in US$ Thousand by Testing Method: 2020 to 2027
    Testing Method in US$ Thousand: 2012-2019
    Table 30: D-dimer Testing Market in Canada: Percentage Share
    Breakdown of Sales by Testing Method for 2012, 2020, and 2027
    Analysis in US$ Thousand by Application: 2020 to 2027
    Table 32: D-dimer Testing Market in Canada: Summarization of
    Table 34: Japanese Market for D-dimer Testing: Annual Sales
    Table 35: D-dimer Testing Market in Japan: Historic Sales
    Testing in US$ Thousand by Application: 2020 to 2027
    US$ Thousand by Testing Method: 2012-2019
    Table 42: Chinese D-dimer Testing Market by Testing Method:
    Percentage Breakdown of Sales for 2012, 2020, and 2027
    Table 47: D-dimer Testing Market in Europe: A Historic Market
    Forecasts in US$ Thousand by Testing Method: 2020-2027
    Opportunity in US$ Thousand by Application: 2020-2027
    Table 53: D-dimer Testing Market in Europe: Summarization of
    Table 55: D-dimer Testing Market in France by Testing Method:
    US$ Thousand by Testing Method: 2012-2019
    France in US$ Thousand by Application: 2020-2027
    Table 60: French D-dimer Testing Market Share Analysis:
    A 17-Year Perspective by Application for 2012, 2020, and 2027
    Table 61: D-dimer Testing Market in Germany: Recent Past,
    US$ Thousand by Testing Method: 2012-2019
    Table 64: D-dimer Testing Market in Germany: Annual Sales
    US$ Thousand by Testing Method: 2012-2019
    Table 69: Italian D-dimer Testing Market by Testing Method:
    Percentage Breakdown of Sales for 2012, 2020, and 2027
    Table 73: United Kingdom Market for D-dimer Testing: Annual
    Table 74: D-dimer Testing Market in the United Kingdom:
    D-dimer Testing in US$ Thousand by Application: 2020 to 2027
    Forecasts in US$ Thousand by Testing Method: 2020-2027
    Opportunity in US$ Thousand by Application: 2020-2027
    Table 83: D-dimer Testing Market in Rest of Europe:
    in US$ Thousand by Testing Method: 2012-2019
    Asia-Pacific in US$ Thousand by Application: 2020-2027
    in US$ Thousand by Application: 2012-2019
    Table 90: Asia-Pacific D-dimer Testing Market Share Analysis:
    A 17-Year Perspective by Application for 2012, 2020, and 2027
    Forecasts in US$ Thousand by Testing Method: 2020 to 2027
    by Testing Method in US$ Thousand: 2012-2019
    Table 93: D-dimer Testing Market in Rest of World: Percentage
    Share Breakdown of Sales by Testing Method for 2012, 2020, and
    Demand Analysis in US$ Thousand by Application: 2020 to 2027
    Table 95: D-dimer Testing Market in Rest of World:

Global Hematology and Coagulation (Lab-based and Decentralized) Markets, 2019-2020 & Forecast to 2024 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 3, 2020

Hematology and Coagulation Markets (Lab-based and Decentralized Markets) examines the current state of two growing testing markets.

Key Points: 
  • Hematology and Coagulation Markets (Lab-based and Decentralized Markets) examines the current state of two growing testing markets.
  • The report contains some discussion of COVID-19 as it relates to the hematology and coagulation markets.
  • Coagulation testing, including d-dimer, is considered to be a growing indicator of the impact and clinical outcomes of patients with COVID-19.
  • The evaluation of the global market for coagulation tests (lab-based and all POC) includes d-dimer as a segment in the market.

Standalone D-dimer Test Strategy May Simplify Diagnosis of Deep Vein Thrombosis

Retrieved on: 
Thursday, October 15, 2020

WASHINGTON, Oct. 15, 2020 /PRNewswire/ --New research suggests that it may be possible to simplify the diagnosis of deep vein thrombosis (DVT) without compromising accuracy.

Key Points: 
  • WASHINGTON, Oct. 15, 2020 /PRNewswire/ --New research suggests that it may be possible to simplify the diagnosis of deep vein thrombosis (DVT) without compromising accuracy.
  • DVT occurs when a blood clot forms in a deep vein, typically in the leg or arm.
  • "We examined the strategy of only using the blood sample D-dimer as the first test to decide which patients need ultrasonography to confirm or rule out DVT."
  • "To our knowledge, this is the first large prospective study to assess the clinical outcomes of a diagnostic strategy using standalone D-dimer," said Dr. Fronas.